Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VICTOR3: Metronomic Chemotherapy Maintenance in TNBC
NCT03358004Phase 2Terminated
- Sponsor
- Mario Negri Institute for Pharmacological Research
- Start
- Jun 2017
- Primary completion
- Sep 2018
- Modality
- DNA Intercalators/Alkylators, Irreversible Covalent Inhibitors, RNA-Targeting Small Molecules
- Countries
- 3
01
Overview
A Phase 2 trial of vinorelbine, capecitabine in triple-negative breast cancer (TNBC), sponsored by Mario Negri Institute for Pharmacological Research. Started Jun 2017; status: terminated.
02
Drugs
vinorelbinecapecitabine
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on NCT03358004.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03358004.